• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

血管内皮生长因子-酪氨酸激酶抑制剂：新机制、高血压预测因素及管理策略

Vascular endothelial growth factor-tyrosine kinase inhibitors: Novel mechanisms, predictors of hypertension and management strategies.

作者信息

Gomez Javier A

机构信息

John H Stroger Jr Hospital of Cook County, United States.

出版信息

Am Heart J Plus. 2022 May 26;17:100144. doi: 10.1016/j.ahjo.2022.100144. eCollection 2022 May.

DOI:10.1016/j.ahjo.2022.100144
PMID:38559889
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10978313/
Abstract

Vascular endothelial growth factor inhibition has become a cornerstone of cancer therapy. Significant adverse effect is associated with these therapies, with hypertension among the most prevalent. We aim to provide a current review of the mechanisms by which these therapies induce hypertension, the risk factors and predictors of the development of hypertension, and management strategies to minimize the risk of cardiovascular complications in patients receiving vascular endothelial growth factor inhibition as part of cancer treatment.

摘要

血管内皮生长因子抑制已成为癌症治疗的基石。这些治疗方法会带来显著的不良反应，其中高血压最为常见。我们旨在对这些治疗方法诱发高血压的机制、高血压发生的风险因素和预测指标，以及在接受血管内皮生长因子抑制作为癌症治疗一部分的患者中降低心血管并发症风险的管理策略进行综述。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/75bf/10978313/fb261fa123e2/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/75bf/10978313/fb261fa123e2/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/75bf/10978313/fb261fa123e2/gr1.jpg

相似文献

1
Vascular endothelial growth factor-tyrosine kinase inhibitors: Novel mechanisms, predictors of hypertension and management strategies.血管内皮生长因子-酪氨酸激酶抑制剂：新机制、高血压预测因素及管理策略
Am Heart J Plus. 2022 May 26;17:100144. doi: 10.1016/j.ahjo.2022.100144. eCollection 2022 May.
2
Cardiovascular diseases in patients receiving small molecules with anti-vascular endothelial growth factor activity: A meta-analysis of approximately 29,000 cancer patients.接受具有抗血管内皮生长因子活性的小分子药物治疗的患者中的心血管疾病：约 29000 例癌症患者的荟萃分析。
Eur J Prev Cardiol. 2018 Mar;25(5):482-494. doi: 10.1177/2047487318755193. Epub 2018 Jan 29.
3
Hypertension in Cardio-Oncology Clinic: an update on etiology, assessment, and management.心血管肿瘤诊所中的高血压：病因、评估及管理的最新进展
Cardiooncology. 2023 Dec 12;9(1):46. doi: 10.1186/s40959-023-00197-8.
4
Cardiovascular Toxicities Associated with Tyrosine Kinase Inhibitors.酪氨酸激酶抑制剂相关的心血管毒性。
Curr Cardiol Rep. 2023 Apr;25(4):269-280. doi: 10.1007/s11886-023-01845-2. Epub 2023 Feb 16.
5
Cardio-Oncology: mechanisms of cardiovascular toxicity.心脏肿瘤学：心血管毒性的机制
F1000Res. 2018 Jan 25;7:113. doi: 10.12688/f1000research.12598.1. eCollection 2018.
6
Role of cardiovascular imaging in cancer patients receiving cardiotoxic therapies: a position statement on behalf of the Heart Failure Association (HFA), the European Association of Cardiovascular Imaging (EACVI) and the Cardio-Oncology Council of the European Society of Cardiology (ESC).心血管影像学在接受心脏毒性治疗的癌症患者中的作用：代表心力衰竭协会（HFA）、欧洲心血管影像协会（EACVI）和欧洲心脏病学会心脏肿瘤学委员会（ESC）的立场声明。
Eur J Heart Fail. 2020 Sep;22(9):1504-1524. doi: 10.1002/ejhf.1957. Epub 2020 Aug 21.
7
[Hypertension and cancer : Dangerous Liaisons].[高血压与癌症：危险关系]
Ann Cardiol Angeiol (Paris). 2022 Nov;71(5):317-320. doi: 10.1016/j.ancard.2022.08.003. Epub 2022 Sep 6.
8
Toxicity of cancer therapy: what the cardiologist needs to know about angiogenesis inhibitors.癌症治疗的毒性：心脏病专家需要了解的关于血管生成抑制剂的知识。
Heart. 2018 Dec;104(24):1995-2002. doi: 10.1136/heartjnl-2018-313726. Epub 2018 Sep 18.
9
Emerging cancer therapies and cardiovascular risk.新兴癌症疗法与心血管风险。
J Thromb Thrombolysis. 2021 May;51(4):837-845. doi: 10.1007/s11239-020-02263-9.
10
Precision cardio-oncology: understanding the cardiotoxicity of cancer therapy.精准心脏肿瘤学：了解癌症治疗的心脏毒性
NPJ Precis Oncol. 2017 Sep 12;1(1):31. doi: 10.1038/s41698-017-0034-x. eCollection 2017.

引用本文的文献

1
Vascular Endothelial Growth Factor-B Blockade with CSL346 in Diabetic Kidney Disease: A Phase 2A Randomized Controlled Trial.CSL346阻断血管内皮生长因子-B治疗糖尿病肾病：一项2A期随机对照试验
J Am Soc Nephrol. 2024 Nov 1;35(11):1546-1557. doi: 10.1681/ASN.0000000000000438. Epub 2024 Aug 16.
2
Critical review of the current and future prospects of VEGF-TKIs in the management of squamous cell carcinoma of head and neck.对血管内皮生长因子酪氨酸激酶抑制剂（VEGF-TKIs）在头颈部鳞状细胞癌治疗中的现状及未来前景的批判性综述。
Front Oncol. 2023 Dec 13;13:1310106. doi: 10.3389/fonc.2023.1310106. eCollection 2023.
3
Adverse effects of tyrosine kinase inhibitors in cancer therapy: pathophysiology, mechanisms and clinical management.

本文引用的文献

1
Increase in Blood Pressure Associated With Tyrosine Kinase Inhibitors Targeting Vascular Endothelial Growth Factor.靶向血管内皮生长因子的酪氨酸激酶抑制剂与血压升高相关。
JACC CardioOncol. 2019 Sep 24;1(1):24-36. doi: 10.1016/j.jaccao.2019.08.012. eCollection 2019 Sep.
2
Vascular toxicities with VEGF inhibitor therapies-focus on hypertension and arterial thrombotic events.血管内皮生长因子（VEGF）抑制剂疗法的血管毒性——聚焦于高血压和动脉血栓形成事件。
J Am Soc Hypertens. 2018 Jun;12(6):409-425. doi: 10.1016/j.jash.2018.03.008. Epub 2018 Mar 21.
3
2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.
酪氨酸激酶抑制剂在癌症治疗中的不良反应：病理生理学、机制和临床管理。
Signal Transduct Target Ther. 2023 Jul 7;8(1):262. doi: 10.1038/s41392-023-01469-6.
4
Established and Emerging Cancer Therapies and Cardiovascular System: Focus on Hypertension-Mechanisms and Mitigation.已确立和新兴的癌症疗法与心血管系统：聚焦高血压——机制与缓解。
Hypertension. 2023 Apr;80(4):685-710. doi: 10.1161/HYPERTENSIONAHA.122.17947. Epub 2023 Feb 9.
2017美国心脏病学会/美国心脏协会/美国医师协会/美国心脏病学学会/美国预防医学学院/美国老年病学会/美国药剂师协会/美国血液学会/美国预防医学学会/美国医学协会/美国初级保健医师学会成人高血压预防、检测、评估和管理指南：美国心脏病学会/美国心脏协会临床实践指南工作组报告
Hypertension. 2018 Jun;71(6):e13-e115. doi: 10.1161/HYP.0000000000000065. Epub 2017 Nov 13.
4
Bevacizumab significantly increases the risks of hypertension and proteinuria in cancer patients: A systematic review and comprehensive meta-analysis.贝伐单抗显著增加癌症患者患高血压和蛋白尿的风险：一项系统评价与综合荟萃分析。
Oncotarget. 2017 May 23;8(31):51492-51506. doi: 10.18632/oncotarget.18190. eCollection 2017 Aug 1.
5
Cardiovascular Toxic Effects of Targeted Cancer Therapies.靶向癌症治疗的心血管毒性作用
N Engl J Med. 2016 Oct 13;375(15):1457-1467. doi: 10.1056/NEJMra1100265.
6
Clinical risk factors for the development of hypertension in patients treated with inhibitors of the VEGF signaling pathway.接受VEGF信号通路抑制剂治疗的患者发生高血压的临床危险因素。
Cancer. 2015 Jan 15;121(2):311-9. doi: 10.1002/cncr.28972. Epub 2014 Sep 18.
7
Hypertension due to antiangiogenic cancer therapy with vascular endothelial growth factor inhibitors: understanding and managing a new syndrome.血管内皮生长因子抑制剂抗血管生成癌症治疗所致高血压：认识和治疗一种新综合征。
Can J Cardiol. 2014 May;30(5):534-43. doi: 10.1016/j.cjca.2014.02.011. Epub 2014 Feb 25.
8
Regorafenib induces rapid and reversible changes in plasma nitric oxide and endothelin-1.regorafenib 诱导血浆一氧化氮和内皮素-1 的快速和可逆变化。
Am J Hypertens. 2012 Oct;25(10):1118-23. doi: 10.1038/ajh.2012.97. Epub 2012 Jul 12.
9
Effects of novel angiogenesis inhibitors for the treatment of cancer on the cardiovascular system: focus on hypertension.新型血管生成抑制剂治疗癌症对心血管系统的影响：聚焦于高血压。
Circulation. 2011 Oct 11;124(15):1687-91. doi: 10.1161/CIRCULATIONAHA.110.992230.
10
Hallmarks of cancer: the next generation.癌症的特征：下一代。
Cell. 2011 Mar 4;144(5):646-74. doi: 10.1016/j.cell.2011.02.013.